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Human diseaseIt has been found that the majority of disease-associated genetic variants identiﬁed by genome-wide association
studies are located outside of protein-coding regions,where they seem to affect regions that control transcription
(promoters, enhancers) and non-coding RNAs that also can inﬂuence gene expression. In this review,we focus on
two classes of non-coding RNAs that are currently a major focus of interest: micro-RNAs and long non-coding
RNAs. We describe their biogenesis, suggested mechanism of action, and discuss how these non-coding RNAs
might be affected by disease-associated genetic alterations. The discovery of these alterations has already con-
tributed to a better understanding of the etiopathology of human diseases and yielded insight into the function
of these non-coding RNAs. We also provide an overview of available databases, bioinformatics tools, and high-
throughput techniques that can be used to study the mechanism of action of individual non-coding RNAs.
This article is part of a Special Issue entitled: From Genome to Function.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Genome-wide association studies (GWAS) have discovered thou-
sands of single-nucleotide polymorphisms (SNPs) that are associated
withmultifactorial diseases and quantitative traits. At the time of writing
of this review (October 2013), the GWAS catalog [1] described 11,680
SNPs associated with diverse phenotypes and quantitative traits. Despite
the wealth of information that GWAS provide, it can be difﬁcult to inter-
pret the results because of the limited resolution of the genome-wide
chips used in the initial genotyping screen. Moreover, even state-of-
the-art technology and approaches, such as using specialized high-
resolution genotyping platforms (for example, the Immunochip [2] and
Metabochip [3]), performing genotype imputation [4], or eQTL analysis
[5], are often not enough to pinpoint the functional SNP and/or causative
gene. What is emerging from these GWAS, however, is that N90% of
disease-associated SNPs are located in non-coding regions of the genome
for example in promoter regions, enhancers, or even in non-coding RNA
genes [1,6]. This indicates that these SNPsmight be regulatory. In a paper
by the Encyclopedia of the DNA Elements (ENCODE) Project Consortium
it was suggested that biochemical functionality could be assigned 80% of
the human genome [7]. While fewer than 10% of the GWAS SNPs affect
coding sequences, most non-coding variants are concentrated in DNA
stretches marked by deoxyribonuclease I (DNase I) hypersensitive sites,
where they seem to perturb transcription factor binding sites or alternome to Function.allelic chromatin states [8]. A small percentage seems to disrupt or create
micro-RNA (miRNA) binding sites in the 3′ untranslated region (3′-UTR)
of genes. All these events will affect the expression level of the genes
regulated by these functional elements and can thereby contribute to
deregulation of pathways that control healthy cell function.
The recent discovery of approximately 13,500 longnon-codingRNAs
(lncRNAs) has changed the view on the human genome (Fig. 1) [9]. It
has been estimated that approximately 7% of SNPs associatedwith auto-
immune diseases seem to annotate to long intergenic non-coding RNAs
(lincRNAs), a subclass of lncRNAs [6], and some GWAS SNPs have been
demonstrated to have eQTL-effects on these lincRNAs [10]. It is thought
that the majority of lncRNAs are somehow involved in regulating the
expression of protein-coding genes and, therefore, SNPs associated
with these ncRNAs may indirectly inﬂuence the expression of proteins
involved in disease. In this review we will describe how two classes of
regulatory ncRNAs, themiRNAs and the lncRNAs, regulate gene expres-
sion. We will also describe how SNPs and other types of genetic varia-
tion that affect these ncRNAs can contribute to disease phenotypes.
2. miRNAs
miRNAs are short regulatory RNAs (approximately 19–24 nucleo-
tides long) involved in post-transcriptional gene regulation. The ﬁrst
miRNA, lin-4, was identiﬁed in 1993 in a screen for genes required for
post-embryonic development in Caenorhabditis elegans [11], but it
took another seven years to discover the second one (let-7) [12]. Since
then, the number of miRNAs has increased steadily. At the time of
writing, the number of human mature miRNAs described in miRBase
Fig. 1. Abundance of regulatory ncRNA species versus protein coding genes in the human genome. The numbers are based on Gencode V17 (http://www.gencodegenes.org/releases/17.html).
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lation of up to 60% of protein-coding genes [14]. A single vertebrate
miRNA has been described as targeting 200 messenger RNAs (mRNAs)
on average, although some miRNAs regulate only a few targets [15].
Conversely, some protein-coding genes are regulated by only a single
miRNA, while others are regulated by many miRNAs [16]. The impor-
tance of miRNAs as ﬁne-regulators of gene expression has become
clear since it was discovered that they play important roles in pivotal
biological processes, such as development, cell proliferation, cell differ-
entiation, and cell death [17–20].Fig. 2.miRNA biogenesis and mechanism of action. Stem loop sequences in primary micro
60–80-nucleotide long precursor microRNA (pre-miRNA) hairpins, which are subsequen
produce two single-stranded RNA strands, each of which can be loaded into the RISC co
the miRNA sequence to the 3′ UTR of the target mRNA.3. miRNA biogenesis and mechanism of action
The process of miRNA biogenesis is quite characteristic for this sub-
class of ncRNAs. The primary miRNA transcript (pri-miRNA) is charac-
terized by one or many hairpins that encompass the functional mature
miRNA in their stem (Fig. 2). Upon recognition by two nuclear enzymes,
Drosha and DGCR8, the pri-miRNA is processed into one or several hair-
pins approximately 70 nucleotides long; these are called precursor
miRNAs (pre-miRNAs). They are exported into the cytoplasm by the
nuclear export protein Exportin 5 (XPO5) [21]. In the cytoplasm, theRNA (pri-miRNA) transcripts are recognized by DROSHA/DGCR8 and processed into
tly translocated by exportin 5. In the cytosol, the pre-miRNA is cleaved by Dicer to
mplex (here represented by Dicer, GW182 and AGO2 proteins), which is guided by
1912 B. Hrdlickova et al. / Biochimica et Biophysica Acta 1842 (2014) 1910–1922pre-miRNA can be recognized and are then processed by the RNase III
enzyme Dicer, which removes the loop of the hairpin, resulting in a
~20 bp dsRNA molecule. One of the strands will be incorporated into
the RNA-induced silencing complex (RISC) containing the Argonaute
protein 2 (AGO2) and the GW182 [22]. The RISC complex will target a
mRNA transcript, based on sequence complimentarity between the
miRNA sequence and nucleotides in the 3′-UTR of the target [23]. It is
thought that binding of the RISC complex to this target leads to direct
Ago-mediated cleavage of the target if the homology between miRNA
and its target is extensive or to deadenylation followed by degradation
of the target mRNA if the homology between the miRNA and its target
is less extensive [22,24]. Efﬁcient targeting requires continuous base-
pairing of themiRNA seed region (stretches of 6–8 nucleotides between
positions 1 and 8 of the mature miRNA) with its target [11,24,25].
Computational target prediction approaches make use of this pro-
posed rule to predict the targets of miRNA-induced silencing. These al-
gorithms are based on searching for perfect Watson–Crick pairing
between the miRNAs' seed-sequence and the target mRNA sequence
(most algorithms focus only on the 3′-UTR of genes) alone, or in combi-
nation with other rules, such as evolutionary conservation criteria to
predict miRNA target sites [14,24]. Evolutionary conservation was im-
portant in deﬁning the ﬁrst identiﬁedmiRNAs [26], but it is now becom-
ing clear that manymiRNAs are species-speciﬁc. In contrast, more than
60% of human protein-coding genes have been under selective pressure
to maintain pairing to miRNAs [27]. miRNAs that appear to have a com-
mon ancestor, and differ only in a few nucleotides, are grouped into the
same miRNA family [28]. Until recently, it was assumed that miRNAs
mainly target the 3′-UTRs of mRNAs [22], but it has now been shown
that miRNA target sites can also be located in the 5′-UTRs of target
mRNAs, or even in the coding region of these RNAs [22,29].
Much attention has recently been paid to miRNA as potential bio-
markers in circulation. Cell-free miRNAs have been described in multiple
human body ﬂuids, such as serum [30,31], saliva [32], cerebrospinal ﬂuid
(CSF) [33], and urine [34]. Most importantly, the disease-speciﬁc or even
disease-stage-speciﬁc nature of circulating miRNA proﬁles [35,36]
implies that circulating miRNAs might potentially be used as novel
biomarkers to evaluate health status or disease progression.
4. A role for miRNAs in disease
miRNAs have been shown to be involved in cancer and in neurode-
generative, cardiovascular and autoimmune diseases [16]. Changes
in the amount of speciﬁc miRNAs will result in downregulation or
upregulation of their targets, leading to deregulation of the pathways
in which those targets are involved. This deregulation of miRNA levels
in human diseases can occur in different ways.
Firstly, altered functions of the enzymes involved in the miRNA
biogenesis pathway have been implicated in human disease.
Haploinsufﬁciency of DGCR8 accounts for over 90% of cases of
DiGeorge syndrome. This dominantly inherited disorder is caused by
the presence of hemizygous chromosome 22q11.2 deletions, which
lead to various phenotypic defects including immunodeﬁciency and
autoimmunity [37]. However, DGCR8 haploinsufﬁciency does not lead
to an overall decrease in miRNA levels [38]. The presence of the XPO5
inactive mutant traps miRNAs in the nucleus in a subset of human
tumors [39]. Defects in Dicer have also been associated with disease,
for example, recurrent somatic missense mutations in DICER1 have
been identiﬁed in non-epithelial ovarian cancers [40]. In conclusion, de-
fects in severalmembers of themiRNAprocessingmachinery have been
reported. However, these changes never lead to dramatic overall chang-
es of miRNA levels in the cell, which is consistent with the notion that
miRNAs are essential for cell survival.
Secondly, as pri-miRNA expression is regulated by RNA polymerase
II and by the transcription factors that regulate the expression of
protein-coding genes, the same epigenetic control mechanisms are
involved in regulating miRNA expression. Transcriptional repression ofmiRNAs by promoter hypermethylation was found in many human tu-
mors [41], for example, the miR-200 family is involved in the control of
the epithelial–mesenchymal transition (EMT). In EMT, epithelial cells
lose their adherence and polarity, and start to migrate. The miR-200
family downregulates ZEB1 (zinc ﬁnger E-box-binding homeobox 1)
and ZEB2 (zinc ﬁnger E-box-binding homeobox 1), two important tran-
scriptional repressors of genes involved in cell adherence (E-cadherin)
and polarity (CRB3 (crumbs protein homolog 3) and LGL2 (lethal
giant larvae)). Thus hypermethylation of miR-200 family members in
cancer leads to upregulation of ZEB1 and ZEB2, leading to decreased
adherence and polarity [42]. Similarly, histone modiﬁcations might
also affect miRNA expression levels. For instance, SIRT1 (sirtuin 1), a
NAD-dependent histone deacetylase involved in control of axon growth
and degeneration, was recently found to directly suppress the expres-
sion of miR-138 in response to peripheral nerve injury [43].
Thirdly, different types of genetic alterations to miRNA genes or
to their regulatory motifs can have deleterious consequences. In fact,
the ﬁrst example of the involvement of miRNAs in cancer was the
description of a deletion of chromosome 13q14 in chronic lymphocytic
leukemia patients. The deleted area contains themiR-15a andmiR-16-1
genes that target the anti-apoptotic/pro-survival gene BCL-2 (B-cell
lymphoma 2) [44] and thus deletion of this region contributes to the
greater survival characteristics of cancerous cells. For the purpose of
this review, wewill focus on themost common type of genetic variants,
SNPs, and show how they affect the function of miRNAs.
5. Genetic variation and miRNA function
There are many ways in which disease-associated SNPS can affect
miRNA levels. Firstly, mutations in miRNA biogenesis genes (Fig. 2)
can affect miRNA processing, which, in turn, can contribute to disease.
For instance, the homozygous presence of SNP rs2073778, located in
DGCR8, was found to be associated with a 4-fold increased risk of non-
muscle bladder cancer progression [45]. Another example is the pres-
ence of SNP rs3742330 (ANG) in the Dicer gene, which is associated
with increased survival of T cell lymphoma patients. Homozygous indi-
viduals carrying the GG genotype had a signiﬁcantly increased overall
survival [46]. The functional consequences of these SNPs have not
been investigated to date.
Secondly, SNPs in pri-miRNA and pre-miRNA can affect miRNA
maturation efﬁciency (Fig. 3A). For example, SNP rs11671784 in the
miR-27a gene reduces gastric cancer risk by impairing the processing
of pre-miR-27a to mature miR-27a [47].
Thirdly, SNPs affecting the promoters of miRNAs can affect expres-
sion of the miRNA in question. SNP rs57095329, which confers risk of
systemic lupus erythematosus (SLE), is located in the miR-146a pro-
moter (Fig. 3B). Individuals carrying the risk allele in the promoter
showed lower expression levels of miR-146a [48].
Fourthly, SNPs can alter the binding efﬁciency of miRNAs to mRNA
targets (Fig. 3C) and SNPs in both miRNAs or in target mRNAs can
affect miRNA–target interaction. An example of such an event is SNP
rs3853839, which is associated with SLE susceptibility in Eastern
Asians [49]. This SNP is located in the 3′UTR of the TLR7 (Toll-like recep-
tor 7) gene and potentially has a negative effect on the binding of miR-
3148. Risk allele carriers of this SNP display an increased TLR7 mRNA
half-life, resulting in increased TLR7 expression levels [50], which
would increase the production of pro-inﬂammatory cytokines, suggest-
ing a role in autoimmunity. SNPs in miRNAs or target mRNAs can also
confer the potential binding to different miRNA–target combinations
(Fig. 3C). A SNP in the 3′ UTR may create a sequence match to the
seed of a miRNA that was not previously associated with the given
mRNA [51]. Gong et al. predicted that 52%of SNPs in the dbSNPdatabase
(release 132) would be able to create novel miRNA binding sites [52].
The identiﬁcation of GWAS SNPs in miRNA target sites helps with
prioritizing functional variants. The ﬁrst GWAS signal that was ex-
plained by polymorphic miRNA targeting was the synonymous SNP
A B
C
Fig. 3.Genetic variants and their inﬂuence onmicroRNAs. (A) SNPs occurring in pri-miRNA sequences can affect miRNA processing. (B) SNPs changing the sequence of thematuremiRNA
can prevent binding to the original target and cause binding to alternative targets. (C) SNPs locatedwithin the 3′-UTR of the target canmodulatemiRNA–mRNA interaction in threeways:
(1) a novelmiRNA binding site is created, (2) amiRNA target site is disabled, and (3) the strength of binding can be attenuated, thematuremiRNA sequence in blue indicates aweakness of
binding and in red shows the strength of binding.
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protein), a GTPase involved in regulating immunity. This SNP confers
risk to Crohn's disease by decreasing the binding of miR-196 [53]. An-
other example is the presence of SNP rs1625579, which is associated
with schizophrenia and located in the intron of a putative primary tran-
script for themir137gene. This SNP alters the seed sequence ofmiR-137,
which is known to regulate neuronal development. Interestingly,
four other genes associated with schizophrenia (TCF4 (transcription
factor 4), CACNA1C (calcium channel, voltage-dependent, L type, alpha
1C subunit), CSMD1 (CUB and Sushi multiple domains 1) and C10orf26
(chromosome 10 open reading frame 26)) contain predicted target-
binding sites for miR-137, suggesting that the expression levels of
these four genes might be affected by multiple mechanisms [54].
The strongest proof for the functionality of a SNP is an expression
quantitative trait locus (eQTL) effect of the SNP on a transcript. In
2012 Gamazon et al. showed that 25% of European 3′-UTR SNPs and
18% of African 3′-UTR SNPs predicted to alter miRNA-binding sites did
indeed have a cis-eQTL effect [55]. In another study using publicly avail-
able eQTL datasets, 26 eQTL SNPs were predicted to create, disrupt,
or change the target site of miRNAs in genes encoding xenobiotic me-
tabolizing enzymes [56].6. Bioinformatic and high-throughput methods for studying
miRNA function
Concurrent with the increase in the amount of data, web-based ap-
plications and online databases have been developed that can be used
to analyze miRNA data. These are shown in Table 1. The usefulness of
the available data is exempliﬁed here by just one example. As
mentioned above, the most powerful indication of a SNP's functionality
is to ﬁnd an eQTL effect. In a recent study SNPs from the HapMap
Consortium [57] located in the 3′ UTRs of genes with cis-eQTL effects
were examined using TargetScan, miRBase, Pictar, TarBase, Patroclesand PolymiRTs described in the table. This in silico analysis identiﬁed
32 3′ UTR SNPs that potentially affect miRNA binding [55].
SincemiRNAsmay havemany targets, high-throughput methodolo-
gies are needed to analyze the data. In the miRNA ﬁeld, promising
approaches involve cross-linking RNA (mRNA and miRNAs) to the
RISC complex, immunoprecipitation of these complexes by capturing
Argonaute proteins (most often antibodies against Argonaute are ap-
plied or cell lines are used that express tagged Argonaute proteins),
and sequencing of the mRNA targets in the complex. Examples of such
techniques are AGO2 HITS-CLIP [58], PAR-CLIP [59], and CLIP-seq [60].
The disadvantage of these assays is that they do not yield informa-
tion on speciﬁc miRNAs binding to speciﬁc targets and, therefore, the
miRNA of interest is often overexpressed to enrich for complexes with
this speciﬁc miRNA. However, in a recent paper by Helwak et al.
CLASH (cross-linking, ligation, and sequencing of hybrids) was de-
scribed [61]. In this method, loaded RISC complexes are ﬁrst cross-
linked, isolated by Argonaute immunoprecipitation, and then the RNA
in these complexes is ligated forming hybrid miRNA–target mRNA
sequences that are sequenced. This provides a high-throughputmethod
to identify the targets to which the miRNAs bind and gives an idea of
which fraction of the RISC complexes in the cell is occupied by speciﬁc
miRNAs.
7. Long non-coding RNAs
Long non-coding RNAs (lncRNAs) are a heterogeneous group de-
ﬁned as transcriptsmore than 200 nucleotides (nt) in length that exhib-
it no coding potential [9,62,63]. They can be isolated from nuclear as
well as cytosolic fractions, may or may not be polyadenylated, 98% are
spliced and ~25% of them display at least two different alternatively
spliced isoforms [9,62,64]. In comparison with protein-coding genes,
lncRNAs have longer, but fewer, exons [9,65]. LncRNA promoter regions
are similarly conserved between vertebrates as promoters of protein-
coding genes. In contrast lncRNA exons are lesswell conserved between
Table 1
Publicly available databases and bioinformatics tools for non-coding RNAs.
ncRNAs Database Link Explanation Ref.
ncRNAs in general Rfam 11.0 http://rfam.sanger.ac.uk/ Database of non-coding RNA families, primarily RNAs with a conserved RNA secondary
structure, including both RNA genes and mRNA cis-regulatory elements
[169]
RNAdb 2.0 http://research.imb.uq.edu.au/rnadb/ Database of mammalian noncoding RNAs [170]
DIANA tools http://62.217.127.8/DianaTools/index.php?r=site/index ncRNA analysisweb server-current emphasis is on the analysis ofmiRNA andprotein coding
genes
–
ncRNA.org http://www.ncrna.org/ Functional RNA Project — bioinformatics tools and databases –
http://www.ncrna.org/software List of bioinformatics tools for RNAs –
UCSC Genome Browserfor functional RNA http://www.ncrna.org/glocal/cgi-bin/hgGateway UCSC Genome Browser with large inclusion of functional RNA related custom tracks and
several enhancements for RNA secondary structure support
[153,154]
http://www.ncrna.org/custom-tracks UCSC Genome Browser — speciﬁc custom tracks for different species (human, mouse, rat,
drosophila) to visualize the data of interest
–
RegulomeDB http://regulome.stanford.edu/index Database annotates SNPs with known and predicted regulatory elements in the intergenic
regions of the human genome
[171]
NONCODE database http://www.noncode.org/NONCODERv3/guide.htm Database that includes almost all types of ncRNAs (except transfer RNAs and ribosomal
RNAs), ncRNA sequences and their related information (e.g. function, cellular role, cellular
location, and chromosomal information)
[172–174]
NPInter http://www.bioinfo.org.cn/NPInter/ Functional interactions between noncoding RNAs (except tRNAs and rRNAs) and
biomolecules (proteins, RNAs and DNAs) which are experimentally veriﬁed.
[175]
small ncRNAs MirBase http://www.mirbase.org/ Online repository for microRNA sequences and their annotations [13]
MicroRNA.org http://www.microrna.org/microrna/home.do Miranda algorithm-predicting microRNA targets. [176]
Target Scan http://www.targetscan.org/ Prediction of microRNA targets (for human, mouse, worm, drosophila, zebraﬁsh) [27]
DIANA-microT-ANN DIANA- http://62.217.127.8/DianaTools/index.php?r=microtv4/index ncRNA analysis web server-current-emphasis is on the analysis of miRNA & protein-coding
genes (incl. miRNA target prediction, analysis of expression data for microRNA function,
incorporating microRNAs in pathways, db. of experimentally supported microRNA targets)
[177]
MicroT-CDS http://62.217.127.8/DianaTools/index.php?r=microT_CDS/index
DIANA-mirExTra http://diana.cslab.ece.ntua.gr/hexamers/
DIANA-miRPath http://www.microrna.gr/miRPathv2
TarBase http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=tarbase/index Available miRNA targets derived from all contemporary experimental techniques [178]
Starbase http://starbase.sysu.edu.cn/ miRNA targets and protein RNA interaction data from CLIP seq experiments [179]
miRmap http://mirmap.ezlab.org/ Prediction of miRNA targets that combines different known approaches [180]
PicTar http://pictar.mdc-berlin.de/ Algorithm for the identiﬁcation of microRNA targets [15]
miRanda http://www.microrna.org/microrna/home.do MiRNA target predictions and expression proﬁles [176]
microSNiPer http://epicenter.ie-freiburg.mpg.de/services/microsniper/ Predicts the impact of a SNP on a putative microRNA binding site [181]
mirdSNP http://mirdsnp.ccr.buffalo.edu/ Database of disease-associated SNPs and microRNA target sites in 3′ UTRs of human genes [182]
mirwalk http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/predictedmirnagene.html Database of predicted and validated miRNA targets [183]
PolimiRTS http://compbio.uthsc.edu/miRSNP/ Database of naturally occurring DNA variation in predicted and experimentally identiﬁed
miRNA target sites
[184]
Patrocles http://www.patrocles.org/Patrocles.htm Database of DNA polymorphisms predicted to disturb miRNA target [185]
miRSNP http://cmbi.bjmu.edu.cn/mirsnp Collection of human SNPs in predicted miRNA–mRNA binding sites. [186]
PITA http://genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html MicroRNA prediction tool for targets sites [187]
Long ncRNAs LNCipedia http://www.lncipedia.org Database for annotated human lncRNA sequences and structure — contains 32,183 human
annotated lncRNAs
[152]
lncRNA Database http://www.lncrnadb.org/ Repository of known lncRNAs in eukaryotic cells with published characteristics— linked to
UCSC genome browser for visualization and to NRED database for expression information
[71]
Human lincRNA catalog http://www.broadinstitute.org/genome_bio/human_lincrnas/ Reference catalog containing over 8000 human lincRNAs [65]
Functional lncRNA Database http://www.valadkhanlab.org/database.php Database containing 204 lncRNAs and their splicing variants, analysis of the lncRNAs and
their comparison to protein-coding transcripts
[188]
ncRNA Expression database (NRED) http://nred.matticklab.com/cgi-bin/ncrnadb.pl Provides gene expression information for thousands of lncRNAs in human and mouse,
contains both microarray and in situ hybridization data
[189]
NONCODE v3.0 http://www.noncode.org/NONCODERv3/ Integrative annotation of long noncoding RNAs [174]
ncFANs http://ebiomed.org/ncfans/ Functional annotation and function enrichment of lncRNAs (human & mouse), using data
from 3 microarray platforms
[190]
Linc2GO http://www.bioinfo.tsinghua.edu.cn/~liuke/Linc2GO/index.html Web-server providing comprehensive function annotation of human lincRNAs [191]
LncRNADisease http://202.38.126.151/hmdd/html/tools/lncrnadisease.html Resource containing experimentally supported lncRNA-disease association data and inte-
grates tool(s) for predicting novel lncRNA-disease associations
[192]
LncBase http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=lncBase/index Part of DIANA tools — predicted and experimentally veriﬁed, miRNA–lncRNA interactions [193]
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type-speciﬁc expression proﬁles [62] and that in their speciﬁc cellular
background they can be expressed at levels, similar to the levels of
protein-coding RNAs. The origin of lncRNAs is still under debate, but a
recent study [67] has reported that more than two-thirds of mature
lncRNA transcripts contain transposable elements (TEs), whereas only
4% of protein-coding genes contain these ‘jumping genes’ [68]. This ob-
servation led to the postulation that themajority of lncRNAs have arisen
via insertion of TEs. For example, the rodent-speciﬁc brain cytoplasmic
RNA 1 (BC1), the anthropoid primate-speciﬁc brain cytoplasmic RNA
200-nucleotide (BC200), and the strepsirhini primate-speciﬁc G22
lncRNAs, form a family of lncRNAs which originate independently
from insertion of TEs, resulting in lncRNAs that locate to dendrites in dif-
ferent mammalian species [69–72].
The ﬁrst lncRNAs (H19 and Xist (X-inactive speciﬁc transcript))were
discovered using traditional gene mapping approaches in the early
1990s [73–75] and were considered to be rare exceptions to the then
central dogma of molecular biology. Using tiling arrays HOTAIR (HOX
antisense intergenic RNA) and HOTTIP (HOXA transcript at the distal
tip) were discovered in the homeobox gene regions (HOX clusters)
[76,77]. In 2009, Guttman et al. were the ﬁrst to describe a genome-
wide approach for discovering lncRNAs that yielded 1600 novel
mouse lncRNAs. In this study gene expression data and the presence
of chromatin marks for promoter regions and gene bodies were inte-
grated with the known annotations of coding transcripts to identify
lncRNAs [66]. Since then, thousands of lncRNAs have been identiﬁed
using similar approaches in the mouse and human genomes [62,78].
When used in combination with next-generation RNA sequencing, ad-
ditional information can be obtained about lncRNA exon–intron struc-
ture as well as about the abundance of these transcripts [79–85].
Cabili et al. combined chromatin marks and RNA-sequencing (RNA-A)
B)
C)
D)
Fig. 4. Classiﬁcation of lncRNAs based on position relative to the nearest protein-coding gene. (
coding genes. (B) Antisense lncRNAs are transcribed from the strand opposite of the protein-co
intronic antisense lncRNAs,when the transcript falls completelywithin the boundaries of an opp
coding gene. (C) Sense lncRNAs are located on the same strand and transcribed in the same d
located on the antisense strand (opposite of the protein-coding gene) and their transcription st
in the opposite direction relative to the protein-coding gene. Color legend: protein coding genseq) data to generate the human lincRNA catalog, containing more
than 8000 lincRNAs determined across 24 different human cell types
and tissues [65]. Although more than 13,500 human lncRNAs have
been annotated by GENCODE, only a few dozen have been studied in
more detail so far. The challenge is now to elucidate the function of
these lincRNAs.
8. Classes of lncRNAs and mechanism of action
8.1. Classiﬁcation of lncRNAs based on genomic location
The size limit of N200 nucleotides used to deﬁne lncRNAs is an arbi-
trary cut-off based on RNA isolation protocols and their size exclusion
limit in the past, which potentially leads to the capture of a heteroge-
neous group of different transcripts with respect to function. Although
different nomenclatures are used, in this review we will adhere to the
classiﬁcation based on the lncRNA's location relative to the nearest
known protein-coding gene as described in GENCODE [9]. This subclas-
siﬁcation leads to four broad categories (Fig. 4). The long intergenic
non-coding RNAs (lincRNAs) are the largest group of lncRNAs, account-
ing for approximately 6000 human genes according to the GENCODE
dataset V17 [9] or approximately 8000 according to the human lincRNA
catalog [65]. LincRNA genes do not overlap or lie in close proximity to
protein-coding genes [66,86]. The second most prevalent class of
lncRNAs is the antisense lncRNA that is transcribed from the strand op-
posite of the protein-coding genes, which they are overlapping. Based
on their complete or incomplete overlap, antisense lncRNAs can be
subdivided into various subclasses, for example, intronic antisense
lncRNAswhen the lncRNA transcript falls completelywithin the bound-
aries of an opposing coding intron, or natural antisense transcripts
(NATs) with partial overlap, mainly around the promoter or terminatorA) Long intergenic non-coding RNA (lincRNA) genes do not overlap or neighbor protein-
ding genewith whom they are overlapping. Antisense lncRNAs can be subdivided into (1)
osing coding intron; or (2) natural antisense transcripts (NATs)whichpartially overlap the
irection as a neighboring protein-coding gene. (D) Bidirectional or divergent lncRNAs are
art site (TSS) is close to the TSS of the protein-coding gene. These lncRNAs are transcribed
es (blue) and lncRNA genes (red).
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that the sense–antisense pairs are often co-expressed together, that
they share a similar pattern of evolutionary conservation [89], and
that the antisense transcriptmodulates the expression of the sense tran-
script by the formation of a sense–antisense RNA duplex [88]. The third
subclass of lncRNAs comprises the sense lncRNA transcripts, which can
be ‘sense intronic’ or ‘sense overlapping’. Such transcripts are located on
the same strand and transcribed in the same direction as a protein-
coding gene. This organization is much less prevalent. In total, fewer
than 1000 sense lncRNAs have been identiﬁed, overlapping completely
or partially with protein-coding genes. To date, this subclass is poorly
characterized compared with the other lncRNAs. The fourth subclass
of lncRNAs is the bi-directional or divergent group. These transcripts
are located on the antisense strand (opposite of the protein-coding
gene); they have their transcription start site (TSS) close to the TSS of
the protein-coding gene, but are transcribed in the opposite direction.
The majority of these bi-directional pairs are co-expressed together
and conserved between human and mouse [90,91].8.2. Classiﬁcation of lncRNAs based on molecular mechanism (lncRNA
archetypes)
LncRNAs can interact with DNA or RNA aswell as proteins. Although
for most of the annotated lncRNAs the detailed mechanism of action is
still unknown, the few examples available show the complexity of
lncRNA biology. LncRNAs control multiple mechanisms and have been
implicated in post-transcriptional gene regulation by controlling pro-
cesses, like protein synthesis, RNA maturation, and RNA transport, and
have been shown to control transcriptional gene silencing via epigenetic
regulation and chromatin remodeling [82,92–96].A)
B)
C)
D)
Fig. 5. Four archetypes of lncRNAmechanismof action. (A) Signaling archetype: some lncRNAs a
(B) Decoy archetype: some lncRNAs competewith another sequence/structure (such asmiRNAs
that bind speciﬁc proteins and transport them closer to speciﬁc target sequence. This interactio
plex) binds directly to DNA, or (2) indirect—when the interaction between lncRNA–protein ism
multiple proteins, bringing them in close proximity to facilitate interactions and, for example,
Adapted fromWang and Chang [93].In 2011,Wang and Chang [93] divided lncRNAs into four archetypes
based on their molecular mechanism (Fig. 5). It is important to state
here that some lncRNAs are known to exercise more than one of these
archetypal molecular mechanisms. LncRNAs that are deﬁned to belong
to display the signaling archetype act as a molecular signal (marker)
for a particular biological state or condition (e.g. intracellular signaling
or response to a stimulus) rather than on the function/mechanism
that theymight exert. The presence or absence of this signal can indicate
what is happening in the given cell in that moment and may activate
or silence other genes without the need for translation (Fig. 5A).
For instance the presence of Xist indicates that one of the X chromo-
somes is actively being epigeneticly silenced. Examples of lncRNAs
displaying the signaling archetype are lncRNAs involved in embryonic
development (HOTAIR and HOTTIP) [76,77,97], DNA damage response
(e.g. lincRNA-p21 and PANDA (p21-associated ncRNA DNA damage
activated lncRNA)) [98,99], stress responses (e.g. COLDAIR (cold-
assisted intronic non-coding RNA) and COOLAIR (cold-induced long an-
tisense intragenic RNA)) [100,101], and somatic cell reprogramming
(e.g. lincRNA-ROR (regulator of reprogramming)) [102,103].
The second mechanism of action is the decoy mechanism (Fig. 5B)
exerted by e.g. GAS5 (growth arrest-speciﬁc transcript 5), MALAT1
(metastasis-associated lung adenocarcinoma transcript 1), TERRA
(telomeric repeat-containing RNA) and PANDA. These lncRNAs can act
as decoys that bind to and interfere with the function of other RNAs or
proteins (miRNAs, transcription factors, or RNA-binding proteins).
They act by competingwith another sequences or structures for binding
and are considered to benegative regulators. For exampleGAS5 acts as a
decoy glucocorticoid-response element (GRE) and competes with DNA
GREs for binding to the glucocorticoid receptor [104]. PANDA binds to
the transcription factor NF-YA and prevents the activation of NF-YA-
induced pro-apoptotic targets [99,105].ct asmolecular signals activating (1) or silencing (2) other geneswithout own translation.
, transcription factors, or RNA-binding proteins) for binding. (C) Guide archetype: lncRNAs
n might be (1) direct—when the lncRNA–protein heteroduplex (ribonucleoprotein com-
ediated via another protein located on theDNA. (D) Scaffold archetype: lncRNAs that bind
allow the formation of ribonucleoprotein complexes.
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archetype, for example, by binding chromatin modifying proteins and
transporting the created complex to speciﬁc targets, for example, chro-
matin modiﬁcation enzymes to DNA, where the interaction may
be directly between this complex and the DNA, or indirectly with het-
eroduplex protein–DNA (Fig. 5C). These lncRNAsmay interact as activa-
tors or repressors with neighboring (cis) or distant (trans) genes.
Examples of lncRNAs employing this mechanism are HOTAIR, lincRNA-
p21, Xist, COLDAIR and Jpx (just proximal to XIST).
The fourth archetype is acting as a scaffold (Fig. 5D), for instance by
bringing bound proteins into a complex or in spatial proximity. Exam-
ples of lncRNAs exploiting this strategy are ANRIL (antisense ncRNA in
the INK4 locus), which functions as a scaffold for the chromatin remod-
eling complexes PRC1 (polycomb repressive complex 1) and PRC2
(polycomb repressive complex 2) [106], HOTAIR (scaffold for PRC2
binding it to the LSD1 (lysine-speciﬁc demethylase 1A) complex) [76,
97,107], and TERC (telomerase RNA component) that scaffolds the
telomerase complex [108].
9. LncRNAs in human disease
In many diseases the expression of protein-coding genes is
deregulated and evidence is now accumulating that altered lncRNA
function might be one of the causes involved. Belowwe describe exam-
ples of lncRNAs involved in the etiopathology of different disorders.
Many lncRNAs have been described that exhibit altered expression
levels in cancer cells compared to healthy tissue of the same origin
[109].MALAT1, also known as NEAT2 (nuclear-enriched abundant tran-
script 2), was initially discovered as a predictive biomarker for metasta-
sis development in lung cancer [110,111]. It took almost ten years to
unravel its mechanism of action. MALAT1 acts by inducing the expres-
sion of metastasis-associated genes [112] and recently it was shown
that in vitro metastasis of EBC-1 cells (human lung cancer cells)
can be inhibited by antisense oligonucleotides directed to MALAT1
[112,113].
LncRNA HOTAIR interacts with PRC2 and alters chromatin to a
metastasis-promoting state [114]. In approximately one-quarter of
human breast cancers, HOTAIR is highly induced, while its elevated
levels are also predictive of metastasis and disease progression in
other cancers, such as colon, colorectal, gastrointestinal, pancreatic
and liver cancer [107,115–118]. ANRIL, GAS5 and lincRNA-p21 are
involved in the escape of growth suppression by regulating tumor sup-
pressor genes (ANRIL) or apoptosis regulators (GAS5, lincRNA-p21).
TERRA and TERC (telomerase RNA component) regulate replicative im-
mortality [119,120]. MALAT1 and HOTAIR activate cancer invasion and
metastasis by respectively regulating cell motility-related genes
(MALAT1) or retargeting of PCR2 complex resulting in a metastasis
promoting chromatin state (HOTAIR) [107,112,121]. The lncRNAs αHIF
(antisense to hypoxia inducible factor α (HIFα)) and tie-1AS (tyrosine
kinase containing immunoglobulin and epidermal growth factor
homology domain-1 antisense) induce angiogenesis [86,122]. PCGEM1
(prostate-speciﬁc transcript 1), UCA1 (urothelial cancer associated 1,
also known as CUDR, cancer upregulated drug resistant), SPRY4-IT1
(SPRY4 intronic transcript 1), and PANDA are involved in suppressing
apoptosis [99,123–125]. Some lncRNAs have, as yet, only been associat-
ed with one speciﬁc type of cancer. PCGEM1, PCA3 (prostate cancer an-
tigen 3, known also as DD3, differential display code 3) and PCNCR1
(prostate cancer ncRNA 1) are involved in prostate cancer, while HULC
(highly up-regulated in liver cancer) is involved with liver cancer
[123,126–130]. In contrast, other lincRNAs (e.g. HOTAIR and MALAT1)
appear to be broadly deregulated in carcinogenesis [110,116,117,131,
132].
More recently, data has been generated that shows that lncRNAs also
have roles in other diseases. Some human pathological phenotypes are
caused by epigenetic changes and imprinted lncRNA gene clusters have
been associated with these diseases [133]. Examples of these are theimprinting-related, neurogenetic Angelman syndrome and Beckwith–
Wiedemann syndrome (BWS) [134]. Angelman syndrome is caused by
a loss-of-function of ubiquitin-protein ligase E3A (UBE3A), also known
as E6AP [135]. Although in the majority of human tissues, both copies
of the UBE3A gene are expressed, in neurons one copy is silenced by
UBE3A-AS1 (ubiquitin-protein ligase E3A antisense RNA 1) [136]. In
patients suffering from Angelman syndrome, the other (active) allele
has either been deleted or inactivated [136].
LncRNAs have also been associated with other neurological disor-
ders, such as BACE1-AS or BC200 in Alzheimer disease,HAR1 (human ac-
celerated region 1 lncRNA) in Huntington disease, and ATXN8OS (Ataxin
8 opposite strand lncRNA) in spinocerebellar ataxia type 8 [134,137,
138]. In Alzheimer disease, the protein-coding gene BACE-1 (β-site am-
yloid precursor protein-cleaving enzyme) cleaves amyloid precursor
protein (APP) to β-amyloid peptide (Aβ), the accumulation of which
(amyloid plaques) is associatedwith disease. LncRNA BACE1-AS, located
on the antisense strand to BACE1, binds complementarily to BACE1
mRNA, increases its stability, regulates BACE1 translation, and thereby
the production of Aβ [139]. BACE1-AS also prevents miRNA-induced re-
pression of BACE-1 bymasking thebinding site formiR-485-5p, by com-
peting for the same region on exon 6 of BACE-1 [140]. Two- to three-fold
increased levels of BACE1-AS and a smaller increase (1.5×) of BACE-1
have been documented post mortem in the brains of patients with
Alzheimer disease [139].
Besides their actions in cancer and neurological diseases, lncRNAs
also exhibit aberrant expression in other disease states, such as
facioscapulohumeral muscular dystrophy (FSHD). FSHD is a common,
progressive, genetic disease of skeletal muscle caused by deletions
that reduce the number of D4Z4 repeats in the FSHD locus at chromo-
some 4q35 [134,141]. Under physiological conditions, D4Z4 repeats re-
cruit Polycomb complexes resulting in chromatin reorganization and
causing repression of 4q35 genes [142]. In contrast, in FSHD patients, a
deletion of D4Z4 repeats results in cis production of the DBE-T lncRNA
that binds to protein complexes, reorganizes the chromatin state of
the FSHD locus, and reactivates the repressed 4q35 genes [142].
10. Genetic variants and lncRNA function
As yet, how far lncRNAs are affected by genetic alterations related to
the disease phenotype is unknown. The larger alterations, like chromo-
somal rearrangements (translocations, ampliﬁcations, or deletions) do
affect the expression of lncRNAs that are involved in disease phenotypes.
For example, two different balanced translocations (t(8;12)(q13;p11.2)
and t(4;12)(q13.2-13.3;p11.2)) affecting chromosome 12p have been as-
sociated with the human brachydactyly type E phenotype [143,144]. The
lncRNA DA125942 in the affected 12p region was recently described as
interacting in cis with Parathyroid hormone-like hormone (PTHLH,
which is a regulator of endochondral bone development) and in trans
with SOX9 (Sex determining region Y-box 9, which acts during chon-
drocyte differentiation) [103,143]. Another balanced translocation
(t(1;11)(q42.1;q14.3)) has been associated with schizophrenia and
other psychiatric disorders [145,146]. This particular translocation af-
fects two genes, the protein-coding disrupted in schizophrenia 1 gene
(DISC1) and the antisense lncRNA disrupted in the schizophrenia 2
gene (DISC2) [146,147]. The sameDISC1/DISC2 regionwas also associated
with a 1q42 deletion in an autism spectrum disorder [148].
The interactions of lncRNAs with other molecules are probably
governed by lncRNA structure, rather than by sequence. As it is difﬁcult
to predict the structure of larger RNAmolecules, it is a challenge to un-
derstand how small mutations (small insertions/deletions or SNPs) are
involved in disease etiopathology. Herewe describe a few scenarios that
can be envisioned. Firstly, SNPs may affect the expression level of
lncRNAs. SNPs can be located in promoter sequence and directly alter
the expression of lncRNAs (loss-of-function, Fig. 6A) or change the bind-
ing of inhibitory complexes, thereby allowing expression of lncRNAs
that are not expressed under physiological circumstances (gain-of-
AC
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D
Fig. 6. Functional consequences of mutations on lncRNAs and their function. Mutations located in regions involved in transcriptional control (e.g. promoters, enhancers) might result in:
(A) direct alteration of the amount of lncRNA transcripts (loss-of function); or (B) indirect alteration of lncRNA levels when enhancer or repressor sites are affected (gain-of-function).
Mutations located in exons of lncRNAs might result in alternative splicing leading to loss-of-function (C). Mutations might also alter lncRNA function by affecting their secondary
structure (D).
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native splicing of the transcript (Fig. 6C) or affect its secondary structure
(Fig. 6D). This can lead to an altered function of the lncRNAs. For in-
stance, the chromosomal region 9p21 (previously described as a “gene
desert”) harbors the ANRIL lncRNA (also known as CDKN2BAS or
CDKN2B-AS1). Many SNPs located within or around this lncRNA have
been associated in GWAS with a susceptibility to atherosclerotic vascu-
lar disease, coronary artery disease, stroke, myocardial infarction, aortic
aneurysm, type 2 diabetes, and several types of cancers [149,150]. Ex-
actly how these SNPs contribute to disease is not yet known. It is unclear
whether they directly regulate the expression level of ANRIL or whether
they disturb the binding site of transcription factor STAT1 (ANRIL's
repressor) in ANRIL's enhancer [151]. SNPs may also modulate ANRIL
transcripts by inducing exon skipping, resulting in shorter splice vari-
ants with reduced efﬁciency or non-functional isoforms [149].11. Bioinformatics tools and high-throughput applications for
studying lncRNAs
As lncRNAs are a relatively novel class of transcripts, there are not
yet many bioinformatics tools to aid the study of lncRNA function.
To date, a couple of lncRNA databases and catalogs are available
(Table 1), such as LNCipedia [152], LncRNAdb [71], and the Human
lincRNA catalog [65]. LncRNAdb contains a comprehensive collection
of eukaryotic lncRNAs and relevant information, such as RNA sequence,
structure, genomic location, expression proﬁles, subcellular localization,
conservation and function [71]. TheHuman lincRNA catalog [65] focuses
only on human lincRNAs and containsmore than 8000 lincRNAs deﬁned
by more than 30 properties. Expression data across 24 tissues and
cell types is available in this database. Data from both databases can
be visualized and analyzed using the University of California Santa
Cruz (UCSC) genome browser [153]. In the same browser, it is also pos-
sible to annotate ncRNAs with the latest updated genome-wide data
from large international consortia, such as ENCODE (GENCODE dataset)and Functional Annotation of the Mammalian Genome (FANTOM)
[154–156].
Co-expression analysis is a promising strategy to predict themecha-
nism of action of lncRNAs of interest. This type of analysis predicts func-
tions for molecules of unknown gene products, based on co-expression
data and taking into account the known functions or mechanisms
of the co-expressed genes (“guilt by association”). Two examples
of such tools are Gene Network (www.genenetwork.nl/genenetwork)
(Karjalainen and Franke et al., manuscript in preparation) or Gemma
(http://www.chibi.ubc.ca/Gemma/home.html) [157]. However, the data
most commonly used for these analyses comes from arrays. Although
nearly all the arrays were designed to study the expression of protein-
coding genes, several of them also carry probes for lncRNAs. Kumar
et al. took advantage of this and used microarray data to investigate the
association of SNPs with the expression levels of lincRNAs by using
eQTL and a platform containing approximately 2000 lncRNA probes
[10]. They discovered 112 cis-regulated lincRNAs, of which 45%were rep-
licated in an independent dataset. A remarkable 75% of these SNPs affect-
ed the expression of the lincRNA but did not affect the expression of
neighboring protein-coding genes. Expression microarray platforms
probing both protein-coding transcripts and non-coding RNAs will
enable co-expression analyses of these RNA classes. The data can then
be used to link lncRNAs to pathways, using existing data for the coding
genes with which they are co-expressed.
In the near future, enough transcriptomic data is expected to be gen-
erated by next-generation sequencing to allow in depth co-expression
analysis. The initial studies in the ﬁeld were mostly focused on lncRNAs
in the polyadenylated (polyA+) RNA fraction. More recently, a signiﬁ-
cant proportion of lncRNAs also present in the non-polyadenylated
(polyA−) RNA fraction have been described [158]. For this reason, the
latest focus is on both RNA fractions (polyA+, polyA−) and ondifferent
subcellular compartments (nuclear, cytoplasmic) [62,64]. It is expected
that many more lncRNA transcripts will be identiﬁed [159].
Because lncRNA function is based on RNA structure rather than on
RNA sequence, it is difﬁcult to predict lncRNA targets or to pinpoint
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cently been described – Triplexator – that can be used to predict regions
where chromatin-associated RNAs could interact with the DNA double
helix (thereby forming a triple helix structure) [160]. These predicted
sites might pinpoint genes that are regulated by lncRNAs.
The techniques used for the genome-wide identiﬁcation of lncRNA
targets and binding partners employ methods similar to the ones de-
scribed above for ﬁnding miRNA targets. Chromatin Isolation by RNA
Puriﬁcation (ChIRP) [161] and Capture Hybridization Analysis of RNA
Targets (CHART) [162] are based on cross-linking RNA in complex
with DNA and/or protein, followed by capture techniques targeting
the lncRNA in the complex. Subsequently, the protein component
or DNA sequences in the complexes can be identiﬁed by mass spectro-
photometry [161] or next-generation sequencing, respectively. Con-
versely, since lncRNAs have been reported to be involved in targeting
chromatin-modifying complexes to speciﬁc DNA sequences, one can
cross-link complexes and immunoprecipitate these (e.g. the PRC2 com-
plex), and then analyze the RNA component by sequencing (RNA
immunoprecipitation-sequencing (RIP-SEQ)) [163]. Finally, lncRNAs
can be synthesized in vitro and hybridized with protein microarrays to
identify lncRNA–protein interactions [91].
12. Perspectives
The rapid evolution of next-generation sequencing technologies
and the expected drop in cost of assays mean that we will soon be
able to sequence large numbers of genomes and transcriptomes. This
will ultimately provide us with a nearly complete overview of disease-
associated genetic variation. Transcriptome analysis will discover tens
of thousands of new transcripts, many of which will be of a non-
coding nature [159]. Most of the genetic variation associated with com-
plex diseases is located within genomic regions that control transcrip-
tion, rather than in protein-coding areas. As the ncRNAs are now
emerging as important regulators of expression, it is becoming clear
that deregulation of gene expression might be the lynch-pin in many
disease mechanisms. Because of the above it is essential to understand
the function of ncRNAs in health and disease.
What is already emerging andwill complicate the study of the regula-
tory involvement of ncRNAs in human diseases even more, is that differ-
ent classes of ncRNAs might interact. A few lncRNAs have been reported
to be precursors for different types of small ncRNAs, such as miRNAs or
small nucleolar RNAs [62,164]. In addition, miRNAs and lncRNAs can reg-
ulate each other's expression. For example, Zhang et al. reported miR-21
which is able to negatively regulate the expression of the GAS5 lncRNA.
On the other hand GAS5was able to repress miR-21 [165]. LncRNAs can
also act as microRNA ‘sponges’. The most striking example is the circular
lncRNA CDR1 (cerebellar degeneration-related protein 1), which has
been shown to contain approximately 70 binding sites for miR-7. By
binding miR-7 molecules CDR1 prevents binding of this miRNA to other
miR-7 targets [166,167].
The availability of genomic and transcriptomic data will also lead to
an increase in the number of ncRNA eQTLs associated with disease [10].
Once the causal mutations have been connected to speciﬁc ncRNAs, the
next step will be to identify the targets/interaction partners of these
transcripts, which is essential to fully understand the mechanism of
disease. Because both miRNAs and lncRNAs may act on many targets,
high-throughput methods will need to be designed and applied. Even-
tually, genome-editing techniques might be applied to pinpoint the ef-
fects of a single SNP or of small deletions/insertions by allowing
alterations of wild-type alleles into risk alleles in eukaryotic cells [168].
The ‘omics’-revolution started with the description of the sequence
of the human genome. Since then state-of-the-art high-throughput
techniques and bioinformatic approaches have been developed,
that were used to identify mutations that are associated with human
diseases. It has now become apparent that a signiﬁcant part of these
mutations affect the expression or function of ncRNAs. Because bothmiRNAs and lncRNAs exhibit cell type, and even cell developmental
stage speciﬁc expression proﬁles, it is pivotal that this research will be
performed in the relevant (disease associated) cell types. The identiﬁca-
tion of disease SNPs associated with ncRNAs is an important step in
linking ncRNAs to human disease, but to fully understand how these
SNPs contribute to pathology the functions of these ncRNAs need to
be uncovered experimentally. Identiﬁcation of the proteins and path-
ways regulated by these ncRNAs is likely to provide novel insights into
pathology of human diseases, provide novel diagnostic opportunities,
and pinpoint novel therapeutical targets.
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